Page 176 - Drug Class Review

Drug Effectiveness Review Project

placebo 70.6 52.5 100% 0% 0% NR Page 118 of 205

donepezil 5 mg 72.9 62.5 94.9% 2.6% 2.6% NR No significant differences between DON and placebo in quality of life (patient and caregiver) and DON 3 mg/d and 5 mg/d treated patients showed statistically significantly better ADAS-Cog

Alzheimer classification: Mild to moderately severe

donepezil 3mg 71.0 55 92.5% 7.5% 0% NR ome Measures: ADAS-Cog; CGIC Secondary Outcome Measures: ADL; MMSE; CDR-SB; QOL-P (patient); QOL-C (caregiver) Timing of assessments: Screening visit, baseline, and weeks 1, 3, 6, 9, 12 and 14 scores than placebo-treated patients at endpoint (P = 0.036 and P = 0.002, respectively)*; significant differences observed beginning at week 3 No significant differences between DON and placebo in CGIC at endpoint* No significant differences between DON and placebo on MMSE and CDR-SB

Groups similar at baseline: Yes

donepezil 1mg 72.6 72.5 97.6% 2.4% 0% NR Primary Outc Health Outcome Measures: • activities of daily living measures Intermediate Outcome Measures: • • •

e population qualities:

Final Report Update 1 Authors: Rogers et al. Year: 1996 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity: White • Black • Other • Other german OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs